Latest News - Pfizer

Thursday, October 12, 2017 | FDA Approval/Clearance, Headache & Pain, Phase 3/4 Trials, Research and Publications, Pfizer

Once-Daily Lyrica Formulation Wins FDA Approval

The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and t…

Read the full story

Thursday, December 01, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Pfizer

Adjunctive Treatment with Lyrica Found to Reduce Seizure Frequency in Pediatric Epilepsy

New phase 3 results show that Lyrica (pregabalin, Pfizer) Capsules CV is an effective adjunctive therapy for patients with epilepsy between the ages of four and 16 years of age. Specifically, the resu…

Read the full story

Tuesday, August 23, 2016 | FDA Approval/Clearance, Pfizer

FDA Approves Abuse Deterrent Troxyca ER for Pain Management

The FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride, Pfizer) extended-release capsules for the management of pain severe enough to require daily long-term opioid trea…

Read the full story